Background Image
Previous Page  172 / 182 Next Page
Information
Show Menu
Previous Page 172 / 182 Next Page
Page Background

171

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

258

Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients. a

preliminary validation of the opioid risk tool. Pain Medicine 2005; 6: 432-442.

259

Weiner DK, Distell B, Studenski S, Martinez S, Lomasney L, Bongiorni D. Does radio-

graphic osteoarthritis correlate with flexibility of the lumbar spine? Journal of the

American Geriatric Society 1994; 42: 257-263.

260

Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakt-

hrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-

label safety study. Cancer 2009; 115(11): 2571-2579.

261

Wertheim M, Jhangiani H, Niebler G, Charu V. Finding an effective dose of fentanyl

effervescent buccal tablets: combined results of open-label titration. J Clin Oncol 2006;

24(18S): S689.

262

Wheeler M, Birmingham PK, Dsida RM, Wang Z, Coté CJ, Avram MJ. Uptake pharmaco-

kinetics of the fentanyl oralet in children scheduled for central venous access removal:

implications for the timing of initiating painful procedures. Paediatr Anaesth 2002;

12(7): 594-599.

263

Wild MR, Espie CA. The efficacy of hypnosis in the reduction of procedural pain and

distress in pediatric oncology. A systematic review. Journal of Developmental and Beha-

vioral Pediatrics 2004; 25: 207-213.

264

Wong G. Effect of neurolytic celiac plexus block on pain relief, quality of life, and sur-

vival in patients with unresectable pancreatic cancer. Journal of the American Medical

Association 2004; 291: 1092-1099.

265

Younge PA, Nicole MF, Kendall JM. A prospective randomised pilot comparison of intra-

nasal fentanyl and intramuscular morphine for analgesia in children presenting to the

emergency department with clinical fractures. Emerg Med 1999; 11: 90-94.

266

Zarth R, Ehmer M, Sittig HB. Oral transmucosal fentanyl citrate for the treatment of

breakthrough pain. Results of a non-interventional study (NIS). Schmerz 2007; 21(6):

545-552.

267

Zeppetella G, Messina J, Xie F, Slatkin NE. Consistent and clinically relevant effects with

fentanyl buccal tablet in the treatment of patients receiving maintenance opioid thera-

py and experiencing cancer-related breakthrough pain. Pain Pract 2010; 10(4): 287-293.

268

Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough

pain in cancer patients admitted to a hospice [published erratum appears in J Pain

Symptom Manage 2001; 21(3): 265].

269

Zeppetella G, Ribeiro MD. Episodic pain in patients with advanced cancer. American

Journal of Hospice and Palliative Care 2002; 19: 267-276.

270

Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain

in cancer patients. Cochrane Database Syst Rev 2006; (1): CD004311.

271

Zeppetella G, Ribeiro MD. Pharmacotherapy of cancer-related episodic pain. Expert

Opinion on Pharmacotherapy 2003; 4(4): 493-502.

272

Zeppetella G. Breakthrough pain should be distinguished from background pain. Guide-

lines in Practice 2009; 12(3): 1-5.

Literaturverzeichnis